SEC 13F Intelligence

Hhlr Advisors, Ltd. / CTKB

Hhlr Advisors, Ltd.’s Cytek Biosciences Inc Position

Does Hhlr Advisors, Ltd. own Cytek Biosciences Inc (CTKB)? Yes — 6.66M shares worth $29M (+1.74% of its 13F portfolio) as of Q1 2026.

Position Value
$29M
Q1 2026
Shares
6.66M
% of Portfolio
+1.74%
Quarters Held
19
currently held

Position History CTKB

Reported value by quarter
Q3 ’21: $187MQ3 ’21Q4 ’21: $143MQ1 ’22: $94MQ2 ’22: $94MQ2 ’22Q3 ’22: $129MQ4 ’22: $89MQ1 ’23: $71MQ1 ’23Q2 ’23: $57MQ3 ’23: $37MQ4 ’23: $61MQ4 ’23Q1 ’24: $45MQ2 ’24: $37MQ3 ’24: $37MQ3 ’24Q4 ’24: $43MQ1 ’25: $27MQ2 ’25: $23MQ2 ’25Q3 ’25: $23MQ4 ’25: $34MQ1 ’26: $29MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20266.66M$29M+1.74%
Q4 20256.66M$34M+1.08%
Q3 20256.66M$23M+0.56%
Q2 20256.66M$23M+0.73%
Q1 20256.66M$27M+0.75%
Q4 20246.66M$43M+1.50%
Q3 20246.66M$37M+0.81%
Q2 20246.66M$37M+0.92%
Q1 20246.66M$45M+0.97%
Q4 20236.66M$61M+1.22%
Q3 20236.66M$37M+0.82%
Q2 20236.66M$57M+1.21%
Q1 20237.70M$71M+1.26%
Q4 20228.68M$89M+1.87%
Q3 20228.76M$129M+3.39%
Q2 20228.76M$94M+2.01%
Q1 20228.76M$94M+1.97%
Q4 20218.76M$143M+2.21%
Q3 20218.76M$187M+2.45%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Hhlr Advisors, Ltd.’s full portfolio or all institutional holders of CTKB.